NEW HAVEN, Conn., Feb. 10, 2020 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced
that Clarivate Analytics plc (NYSE: CCC; CCC.WS), a global leader
in providing trusted insights and analytics to accelerate the pace
of innovation, has named rimegepant to its annual Cortellis "Drugs
to Watch" list, which identifies 11 new drugs scheduled to enter
the market in 2020 and predicted by Cortellis to achieve annual
sales of $1 billion or more (i.e.,
blockbuster status) by 2024.
William 'BJ' Jones, Biohaven's Chief Commercial Officer of
Migraine and Common Diseases commented, "We are appreciative of
this recognition for rimegepant. We believe in its promise to help
many patients with migraine who don't respond to current
therapies." Mr. Jones added, "We have spent the past year building
a well-prepared, modern technology-driven and impressive commercial
organization that is ready to transform Biohaven from an R&D
organization into an organization that can deliver important
medicines to patients."
The Cortellis list and corresponding analyses focus on the
treatment and possible cure for chronic, progressive and often
debilitating diseases and conditions, including drugs which target
the indications of migraine, breast cancer, multiple sclerosis
(MS), and type 2 diabetes.
About Rimegepant
Rimegepant is the first and only calcitonin gene-related
peptide (CGRP) receptor antagonist developed in an orally
disintegrating tablet (ODT) formulation that is currently under
review by the U.S. Food and Drug Administration (FDA) for the acute
treatment of migraine in adults. The activity of a molecule called
CGRP is thought to play a causal role in migraine pathophysiology
by surging during a migraine attack. Rimegepant works by blocking
neurogenic inflammation, decreasing artery dilation (without active
vasoconstriction) and inhibiting pain transmission on the CGRP
receptor.
CGRP Receptor Antagonism
CGRP receptor antagonists represent a novel class of drug
candidates for the treatment of migraine. This unique mode of
action potentially offers an alternative to current agents,
particularly for patients who have contraindications to the use of
triptans, such as those with underlying cardiovascular diseases, or
who either do not respond or have inadequate or inconsistent
response to triptans or are intolerant to them.
About Migraine
Migraine is a debilitating and recurrent disease
characterized by attacks lasting four to 72 hours with multiple
symptoms, including pulsating headaches of moderate to severe pain
intensity that can be associated with nausea or vomiting, and/or
sensitivity to sound (phonophobia) and sensitivity to light
(photophobia). Nearly 40 million people in the U.S. suffer
from migraine and the World Health Organization classifies migraine
as one of the 10 most disabling medical illnesses. There is a
significant unmet need for new acute treatments as more than 90
percent of migraine sufferers are unable to work or function
normally during an attack.
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
combined internal development and research with intellectual
property licensed from companies and institutions including
Bristol-Myers Squibb Company, AstraZeneca, Yale University, Catalent, Rutgers, and ALS Biopharma LLC. Currently,
Biohaven's lead development programs include multiple compounds
across its CGRP receptor antagonist, glutamate modulation, and
myeloperoxidase inhibitor platforms. Biohaven's common shares are
listed on the New York Stock Exchange and traded under the ticker
symbol BHVN. More information about Biohaven is available at
www.biohavenpharma.com.
Forward-Looking Statements
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of the Company's management. All
statements, other than statements of historical facts, included in
this press release regarding the Company's business and
product candidate plans and objectives are forward-looking
statements. Forward-looking statements include those related to:
the expected timing, commencement and outcomes of the Company's
planned and ongoing clinical trials, the timing of planned
interactions and filings with the FDA, the timing and outcome of
expected regulatory filings, including the need for any
REMS or Advisory Committee meetings, the potential
commercialization of the Company's product candidates, the
potential for the Company's product candidates to achieve any
specified level of revenues, the potential for the Company's
product candidates to be first in class or best in class
therapies and the effectiveness and safety of the
Company's product candidates. The use of certain words, including
"believe", "promise", "may", "possible" and "will" and
similar expressions, are intended to identify forward-looking
statements. Various important factors could cause actual results or
events to differ materially from those that may be expressed or
implied by our forward-looking statements. Additional
important factors to be considered in connection with
forward-looking statements are described in the "Risk Factors"
section of the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on February 28, 2019 and
the Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2019, filed with the
Securities and Exchange Commission on November 1, 2019. The forward-looking statements
are made as of this date and the Company does not undertake any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
For further information, contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohavens-rimegepant-named-to-cortellis-2020-potential-blockbuster-drugs-to-watch-list-301001682.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.